Highlights Received full production run of approximately 20,000 BPC-157 transdermal patches, the Company’s lead product candidate Patches are manufactured and independently tested in the United States Marks the Company’s transition from testing to commercialization Each patch delivers 2 mg of BPC-157, consistent with the 95.5% purity and 2.02 mg dose Vancouver, British Columbia–(Newsfile Corp. – July 14, 2026) – The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the “Company” or “BPC”), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the “Patch”), the Company’s lead product candidate. The arrival of this commercial inventory follows the Company’s previously announced order (previously announced here) and represents a key step in the Company’s transition from testing and formulation validation to commercialization.
This excerpt is quoted from the original release. Read the full announcement on Newsfile Corp.
Brief Summary
The Precision Peptide Company Inc. has successfully secured a 20,000-unit production run of its BPC-157 transdermal patches, a significant milestone in its journey towards commercialization of this innovative therapy.
- Key Product: BPC-157 transdermal patches are the lead candidates of the Company.
- Manufacturing: Each patch, delivering 2 mg of BPC-157, meets 95.5% purity standards.
- Transition to Market: This marks a significant shift from testing to actual market readiness.
- Production Location: All patches are manufactured and independently tested in the United States.
Why it matters: This production run signifies the Company’s commitment to advancing peptide therapy in the wellness industry and enhancing investor confidence in future growth.
Read the Full Article
This is a summary of the press release. For the complete article and any additional details, please visit the original source.
Attribution: Original press release by Newsfile Corp on . We provide an AI-generated summary and links for convenience. Always verify details with the original source. Not investment advice. For informational purposes only.